Intensified ADT with apalutamide, with or without abiraterone plus prednisone, for 52 weeks prolonged PSA progression-free survival compared with ADT alone among men with high-risk biochemically recurrent prostate cancer following radical prostatectomy.
How the retail giant will use the sensitive medical data it collects is among the concerns.
Investigators reported findings from the first randomized trial to evaluate the use of metastasis-directed therapy with hormone therapy in patients with oligometastatic prostate cancer.
Investigators characterized the toxicity of stereotactic body radiotherapy for oligometastases from predominantly prostate, colorectal, breast, and lung cancer.
Each 10% increase in PSA screening rates was significantly associated with a 9% decrease in the metastatic prostate cancer rates, according to a study of VA medical centers.
Final results from the TITAN-RCC trial demonstrate improvements in objective response rates compared with nivolumab monotherapy.
PSMA expression on circulating tumor cells in men with mCRPC increases upon disease progression despite treatment with novel antiandrogens.
Ransomware attacks now account for 25% of all data breaches, according to Verizon’s 2022 Data Breach Investigation Report.
More than 80% of Black survey respondents said they were somewhat or very likely to consider enrolling in a clinical trial.
The agency has issued proposed draft recommendations to guide incorporation of cybersecurity protections into medical devices at the time of manufacture.
